Bio
Dr. Cornelia Dekker is a Pediatric Infectious Diseases physician who came to Stanford after a 12-year career in vaccine clinical development at Lederle Biologicals and Chiron Vaccines where she served as Vice President, Clinical Research and Medical Affairs. In this position, she was responsible for the clinical development of 18 vaccine candidates, including those for HSV, HIV, meningococcus A and C, adjuvanted influenza, acellular pertussis-DT, hepatitis A, hepatitis B, hepatitis C, H. influenza type b and CMV. During her tenure, Chiron’s clinical program included testing of a recombinantly produced HSV gD2/gB2 vaccine with MF59 adjuvant for the amelioration of established genital herpes infection and the prevention of genital herpes in high-risk adults, and the first influenza vaccine combined with the MF59 adjuvant that was licensed intially in Europe and South America and just recently also in the US.
Dr. Dekker joined the Stanford University School of Medicine faculty in the Division of Pediatric Infectious Diseases and was named Medical Director of the Stanford-LPCH Vaccine Program in 1999. She has served as the Stanford PI on NIH-sponsored Vaccine and Treatment Evaluation Unit subcontracts to study new vaccine candidates and on a CDC-sponsored Clinical Immunization Safety Assessment Center contract evaluating safety of licensed vaccines. She leads the Stanford Clinical Core for NIH-sponsored studies looking at the detailed immune responses to influenza vaccines in children compared with young and elderly adults that has expanded to investigate genetic factors by also studying responses of identical and fraternal twins. Dr. Dekker’s expertise in vaccines has been tapped by NIH to serve on several vaccine safety and data monitoring boards, and she currently is Chair of the HIV Vaccine Trial Network Safety Monitoring Board. On the National Vaccine Advisory Committee, she served on the Vaccine Safety Working Group and H1N1 Vaccine Safety Subgroup among others. In 2016, she was named Medical Director for the Stanford Clinical and Translational Research Unit.
Clinical Focus
- Pediatric Infectious Disease
- Vaccine Clinical Trials
- Vaccine Safety
- Influenza, Human
- Clinical Research
Academic Appointments
-
Emeritus (Active) Professor, Pediatrics - Infectious Diseases
-
Member, Child Health Research Institute
Administrative Appointments
-
Medical Director, Stanford-LPCH Vaccine Program (1999 - Present)
-
Medical Director, Stanford Clinical and Translational Research Unit (2016 - Present)
-
IRB Reviewer, Stanford Administrative Panel on Human Subjects in Medical Research, Panel 3 (2002 - Present)
-
Member, Stanford Institute for Immunity, Transplantation and Infection (2005 - Present)
-
Member, Department of Pediatrics Research Advisory Committee (2009 - 2015)
-
Member, Department of Pediatrics Administrative Advisory Committee (2008 - 2009)
-
Member, Stanford GCRC Advisory Committee (2006 - 2008)
Honors & Awards
-
Fellow, Pediatric Infectious Diseases Society (2017-present)
-
Fellow, Infectious Diseases Society of America (1998-present)
-
Member, Pediatric Infectious Diseases Society (1998-present)
-
Junior Faculty Award, SmithKlein Beecham (07/05/00-07/04/02)
-
Excellence in Teaching, Stanford Univ. School of Medicine (06/23/08)
Boards, Advisory Committees, Professional Organizations
-
Chair, NIH DMID SMC: Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area (2017 - Present)
-
Chair, NIH DMID SMC: Phase I Placebo-Controlled Inactivated Whole Virus ZIKA Virus Vaccine in Flavivirus Naive Subjects (2016 - Present)
-
Chair, NIH DMID SMC: A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) with Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects (2016 - Present)
-
Chair, NIH DMID SMC: Phase I Study to Determine the Human Infectious Dose Causing 50% Infection with the GII.2 Snow Mountain Norovirus Filtrate, SNM (2013 - Present)
-
Chair, NIH DMID SMC: Phase I Study of the GII.4 Norovirus Filtrate, CIN 1 (2013 - 2015)
-
Member, NIH DMID SMC: 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 through 74 Years of Age (2012 - Present)
-
Member, External Data Monitoring Committee for ACC-001 (vanutide cridificar) Alzheimer’s disease vaccine (2011 - 2014)
-
Member and Chair, HIV Vaccine Trial Network Safety Monitoring Board (Chair 2014-present) (2009 - Present)
-
Member, NVAC H1N1 Subgroup (2009 - 2010)
-
Member, NIH DMID SMC Evaluation of a Challenge Pool of Norwalk Virus Inocula in Human Subjects (2008 - Present)
-
Member, NVAC Vaccine Safety Working Group (2008 - 2011)
-
Member, NIH DMID Phase 1A Clinical Study with DAS181 Safety Monitoring Committee (2007 - 2010)
-
Member, National Vaccine Advisory Committee (NVAC) (2005 - 2010)
-
Co-chair, NVAC Subcommittee on Vaccine Development and Supply (2005 - 2008)
-
Chair (Pediatric), NIH DMID/Sanofi Pasteur Inactivated Influenza A/H5N1 Vaccine Data Safety Monitoring Board (2005 - 2007)
-
Co-chair, NVAC Working Group on Regulatory Harmonization (2005 - 2006)
-
Member, Trustee Committee, California Association of Independent Schools (2004 - 2007)
-
President, Bentley School Board of Trustees (2001 - 2004)
-
Trustee, Bentley School Board of Trustees (1997 - 2004)
Professional Education
-
Medical Education:Michigan State University College of Human Medicine Office of the Registrar (1976) MI
-
Fellowship:Duke University GME Training Verifications (1982) NC
-
Residency:Duke University GME Training Verifications (1979) NC
-
Internship:Duke University GME Training Verifications (1977) NC
-
Board Certification: Pediatrics, American Board of Pediatrics (1981)
-
B.S., Michigan State University, Microbiology & Public Health, Human Clinical Medicine (1973)
-
M.D., Michigan State University, Medicine (1976)